Abstract
Anal canal carcinoma is highly sensitive to concurrent chemoradiotherapy. Disease-free survival at 5 years, however, declines steeply with the size of the primary tumor, as well as nodal involvement. This Practice Point commentary discusses the findings of a randomized trial by Ajani et al. that compared standard chemoradiotherapy with 5-fluorouracil, mitomycin C and radiotherapy versus induction 5-fluorouracil and cisplatin followed by 5-fluorouracil plus cisplatin plus radiation therapy in the treatment of locally advanced squamous cell carcinoma of the anal canal. Differences in survival at 3 years and 5 years between the two treatments were not significant, but colostomy-free survival was significantly reduced in the induction group. Although the described induction approach should not be implemented in clinical practice, the main limitation of Ajani and colleagues' study is its design, which does not allow the question of whether cisplatin is a viable alternative to mitomycin C to be answered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ajani JA et al. (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299: 1914–1921
Eng C (2006) Anal cancer: current and future methodology. Cancer Invest 24: 535–544
[No authors listed] (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348: 1049–1054
Bartelink H et al. (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15: 2040–2049
Flam M et al. (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14: 2527–2539
Meropol NJ et al. (2008) Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB 9281). J Clin Oncol 26: 3229–3234
Peiffert D et al. (2001) High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol 12: 397–404
Cummings BJ et al. (1991) Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 21: 1115–1125
Patel P et al. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148: 728–736
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors have declared association with the following company: Sanofi-Aventis, as recipients of grant/research support.
Rights and permissions
About this article
Cite this article
Eng, C., Crane, C. & Rodriguez-Bigas, M. Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal?. Nat Rev Gastroenterol Hepatol 6, 16–17 (2009). https://doi.org/10.1038/ncpgasthep1319
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1319
